Based on clinical data and FDA approvals, why do NCCN guidelines for NSCLC recommend erlotinib and gefitinib as first-line systemic therapy in patients with sensitizing EGFR mutations?

Based on clinical data and FDA approvals, why do NCCN guidelines for NSCLC recommend erlotinib and gefitinib as first-line systemic therapy in patients with sensitizing EGFR mutations?

Based on published clinical data and FDA approvals, why do NCCN guidelines for NSCLC recommend erlotinib and gefitinib as recommended (category 1) first-line systemic therapy in patients with sensitizing EGFR mutations?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Byoung Chul Cho, MD, PhD

Professor Byoung Chul Cho, MD, PhD

Yonsei Cancer Center
Yonsei University College of Medicine J
JE-UK Laboratory of Molecular Cancer Therapeutics
Seoul, Korea